BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsEarnings

Conference Call to be Held at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Jul. 23, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today

Related news

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Xeris Biopharma Reports Second Quarter 2026 Financial Results

ABOSAcumen Pharmaceuticals2026-08-05 20:00 EST

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

PRAXPraxis Precision Medicines2026-07-30 20:01 EST

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

TNXPTonix Pharmaceuticals2026-07-27 11:00 EST

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

AXSMAxsome2026-07-14 11:00 EST

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

TSHATaysha Gene Therapies2026-08-04 20:00 EST

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

ECORelectroCore2026-07-30 12:00 EST

electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026

ALKSAlkermes plc2026-07-14 20:00 EST

Alkermes to Report Second Quarter Financial Results on July 28, 2026

View all latest news

Xeris Pharmaceuticals

Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome....

Recent company news

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Xeris Biopharma Reports Second Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

XERSXeris Pharmaceuticals2026-06-30 11:00 EST

Xeris Announces Updates to Its Board of Directors

Stock data

Close
7.36 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States